Currently pharmaceutical targets for treating COVID-19 focus on inhibition of either virus entry (via blocking Spike-ACE2 binding or inhibition of TMPRSS2 activity; for example, camostat mesylate) or virus replication (via inhibition of the virus RNA-dependent RNA polymerase (RdRp); for example, Remdesivir). The gene discussed is CHMP5; the disease is COVID-19.